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1. Introduction  
The process of drug development proceeds through several stages including discovery, 
product characterisation, formulation, delivery and packaging development, 
pharmacokinetics and drug disposition, preclinical toxicology testing and IND 
(Investigational New Drug) application; bioanalytical testing and clinical trials. In general 
this process is time-consuming and expensive. According to statistical data, from among 50 
thousand to 5 million of compounds subjected to screening only 6 become prospective drugs 
and the whole process from discovery to implementation takes from 12 to 24 years and costs 
even up to 800 million USD [1]. The number of new approved drugs partially reflects the 
progress in research and development. Despite enormous financial outlays, there has been a 
steady decrease in the number of drugs introduced each year into therapy. While in the 
1960s about 70-100 new drugs was introduced in the market, in the 1970s, 60-70, in the 1980s 
50, in the 1990s 40 while in 2000th only 20. On the one hand, this is a result of increased 
demands on safety (average number of clinical trials per new drug increased from 30 in the 
1970s through 40 in the 1980s, to 70 in the 1990s), which prolonged the development process 
from 8 years in the 1960s, 12 in 1970s, 14 in 1980s, 15 in 1990s and 21 currently. On the other 
hand, the so-called "easy" to discover drugs have already been discovered. Currently 75% of 
expenditures is absorbed by the research ended in failure and as much as 90% of candidates 
for drug never reach the market.  
Therefore, much effort is directed towards development of new theoretical and 
experimental tools that would increase the effectiveness of the above process, in particular 
in its first stages leading to a decision whether a given compound is a prospective drug or 
not. The necessary and reliable data needed to take such a decision are provided first of all 
by the methods of analytical characterisation of compounds (identification, physical and 
chemical properties, structure), methods permitting optimisation of the leading structure 
(structure-activity relation) and pre-clinical study (toxicity). These early stages of 
pharmacological studies sometimes (but not always) reveal the whole mechanism of action 
of a future drug.  
Recent research work towards drug development has been conducted in two independent 
directions. On the one hand, completely new drugs or pro-drugs (drug precursors that 
become drugs only as a result of metabolic transformations in vivo) are searched for, while 
on the other hand, drugs of second and third generation are proposed that are the improved 
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versions of the so-called first generation ones (e.g. more selective, less toxic, etc.). The search 
for new areas of applications of the already known drugs is conducted independently. It 
should be realised that paradoxically the physico-chemical properties or the mechanism of 
activity of many even commonly used drugs are often unknown. In any case, whenever a 
completely new or well-known compound becomes a candidate promising to be 
therapeutically relevant, it must be characterised by determination of its structure, stability, 
solubility, preferred conditions for maintaining function, toxicity, bioactivity and 
bioavailability. The physico-chemical methods supported by computer modelling at a high 
level of theory should always be the first step in drug characterisation.  
It is well known that magnetic resonance techniques: Nuclear magnetic resonance (NMR) 
discovered by Bloch et al. [2] and Purcell et al. [3] in 1946, and Nuclear quadrupole resonance 
(NQR) originated by Dehmelt and Krüger in 1949 [4] for many years have played invaluable 
role in the process of drug identification, especially when two or more alternative products 
could be synthesized or when geometrical isomers should be differentiated. Despite  their 
usefulness, the potential of these methods in drug development at least at first sight seems 
rather limited in comparison to High-throughput screening (HTS), X-ray diffraction (XRD) or 
Fourier transform infrared spectroscopy (FTIR). Advances of technology over the last decade 
have brought modern spectroscopic techniques that are sensitive tools for such purposes, 
especially in combination with high quality, fast computational quantum chemistry methods 
like Density Functional Theory (DFT). Apart from revealing structural details (geometrical 
isomers, enantiomers), the standard key areas for physico-chemical NMR/NQR studies are 
thermal stability of drugs and structural phase transitions. 
A unique and quite a new area of their use is the study of spatial packing. Most of drugs are 
used in the crystalline form in which the arrangement of molecules forced by weak 
interactions determines their physico-chemical properties (from melting point, solubility to 
polymorphism) and thus affects the performance of the drug. What is more, weak, 
noncovalent and reversible molecular interactions such as hydrogen bondings, van der Waals 
forces, - interactions or metal coordination have been only recently found to be crucial for 
understanding biological activity of drugs and biological processes. As in the absence of 
conformational effects the environmental effect of the crystal influences the electron density 
of a single molecule in a very similar way as the enzyme of a drug molecule in the complex 
drug-enzyme [5], the knowledge of crystal packing provides guidance on the site or method 
of binding. Thus the problems related to understanding the mechanism of formation and 
interplay of weak interactions in crystals have evoked recently enormous interest. 
Additional factor prompting the interest in investigation drugs on molecular level are recent 
advances in genomics and proteomics that have permitted understanding of internal 
mechanisms of human diseases. The latter  cover the knowledge of the genes alteration 
caused by disease, its influence on the proteins encoded by them, the interaction of these 
proteins with each other in living cells, the resulting changes in the specific tissues and 
finally the affect on the entire body. The achievements in this field delimit new directions in 
drug discovery and development of drugs addressing the needs of individual patient. Thus 
new drugs in the near future will be discovered and developed exclusively on the basis of a 
combination of two factors - the understanding of the mechanisms of diseases and 
mechanisms of drugs, both at the molecular level.  
This chapter highlights the importance of combination of experimental and theoretical 
methods in investigation aimed at understanding drugs on the molecular level which is 
fundamental for development of drugs of desirable profiles. 
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2. Directions in drug design 
Throughout the history of medicine the process of new drug discovery has been based on 
natural sources (berries, herbs, leaves, roots, animal parts or minerals) and drugs have been 
discovered by serendipity (sheer luck) or in a trial-and-error process [6]. While until the 
mid-1980s new drugs were discovered mainly by chance, over the next decade, till mid-
1990s, the knowledge of structure was the basis for research, then the starting point was to 
identify a target and a relationship between structure and function. At the beginning of the 
21st century a future direction in drug design has been indicated by the knowledge of the 
human genome, which contains about 23 thousand genes encoding proteins. Although there 
was some success in treating melanoma, HIV or Parkinson disease, the methods involving 
gene therapy, whose aims are personalization of drugs, correction of genetic defects or 
replacement of defective genes are still only a promising methods.  
In the last century the demand for effective drugs has increased and a rational drug design 
has begun to replace old methods. With the progress in the field of chemistry, biology, 
biochemistry, pharmacology, physics and increase in computational power, drug discovery 
has become an interdisciplinary area and entered a new phase called Computer-Aided Drug 
Design (CADD) or Computer-Assisted Molecular Design (CAMD) [7]. The  modern 
methods of rational drug design are capable of designing a biologically active compound, 
drug (ligand) directly interacting with the distinct so-called molecular target (enzyme, 
transporter, ion channel or receptor) or components of a microorganism (bacterium, virus, 
parasite).  
In general, CCAD method allows the search for ligands which are predicted to interact 
strongly with a target or alternatively - the search for a target that will interact strongly with 
a given ligand. In fact molecules of drugs interact in a very specific way with the targets in 
organisms and the result of this interaction may include beneficial or adverse effects as well 
as the excitation of both or biotransformation of the drug [8]. Thus the effective drug design 
is even more complicated as there are three kinds of targets important in drug discovery 
process: therapeutic/biological targets (those which drugs specifically bind to and those 
which elicit therapeutic effects), ADME (absorption, distribution, metabolism, and 
excretion) associated proteins (responsible for  metabolism, important for the efficacy and 
bioactivity study) and adverse drug reaction (ADR)/toxicity targets (major cause for the 
failure of drugs).  
The CADD approaches can be divided into three categories: 
1. the ligand perspective - the structure of a ligand or the structure-activity relationship 
(SAR) are known for a selected ligand and a series of pharmacophores (it requires the 
assumption that both the protein and ligand have limited degrees of flexibility), which 
allows identification of  the target [9,10] 
2. the target perspective - the 3D structure of the target is known, which allows 
identification of the amino acid sequences and their conformations responsible for the 
binding with ligand [11,12].  
3. the ligand-target interaction perspective - the interaction between drug and target is 
known from XDR and NMR structural data [13,14].  
The most popular CADD techniques are receptor-based and ligand-based approaches, the 
former is often called direct while the latter - indirect. Receptor-based drug design requires 
the knowledge of a 3D structure of the biological target and identification of the protein-
binding site or supramolecular host, but the ligand is unknown. Ligand-based drug design 
www.intechopen.com
 
Drug Discovery and Development – Present and Future 
 
234 
uses a known set of ligands with the receptor site unknown. Both approaches are based on 
the lock and key fit of receptor and drug and finally use docking, thus are actually very 
similar. In the receptor-based approach to drug design the structure of a target or a binding 
site is known from 3D XRD or NMR studies, while a ligand fitting the binding pocket of the 
target is searched for in the database, which permits elimination of the need for synthesis of 
new lead compounds. Alternatively the ligand is constructed in such a way as to fit the 
binding pocket (de novo design). The most spectacular achievements of this kind of approach 
was design of the HIV RT inhibitors based on the known HIV reverse transcriptase structure 
[15], development of dorzolamide - a carbonic anhydrase inhibitor, an anti-glaucoma agent 
by Merck [16] or investigation of mechanism of activation of temozolomide and its inhibitor-
target interaction with DNA [17]. If a 3D structure it is not available, the homology model of 
the target can be created on the basis of its amino acid sequence and known structure of 
proteins resembling the target [18,19]. The method makes use of the fact that sequences of 
related proteins are similar and thus the protein structures of naturally occurring 
homologous proteins are also similar  
Indirect drug design is based exclusively on the knowledge of the way different ligands 
bind to an unknown biological target. The structural (in fact stereochemical) and 
physicochemical features of a set of different ligands (active and inactive) allow the creation 
of a hypothetical receptor site - 3D-pharmacophore - determining the minimum set of 
requirements that must be met for the ligand to bind to the target. In fact these requirements 
describe a few specific interactions responsible for the ligand-target binding i.e. define a 
simplified model of the receptor site. The 3D-pharmacophore used in conformationally 
flexible search for ligands provides the best lock-key arrangement with a hypothetical 
receptor site. There are many different methods of construction of a 3D-pharmacophore, 
however the main types are: quantitative structure-activity relationship (QSAR), 
quantitative structure-property relationships (QSPR), molecular shape analysis (MSA), 
receptor surface models (RSM), comparative molecular field analysis (CoMFA), comparative 
molecular similarity index analysis (CoMSIA), pharmacophore mapping (PM) etc. The most 
commonly used are QSAR-based techniques, in which a correlation between the structure 
and biological activity or physico-chemical properties of a ligand is derived.  
In analogy to the direct and indirect approaches in CADD, QSAR techniques can be divided 
to receptor-dependent (RD) and receptor-independent (RI) ones [20].  
In RD-QSAR, models are derived directly from the 3D structures of the multiple ligand-
receptor complex. This group of five methods includes: static ligand representation (3D), 
multiple ligand representation (4D), ligand-based virtual or pseudo receptor models (5D), 
multiple solvation scenarios (6D) and real receptor or target-based receptor model data (7D) 
[21]. Using the structure of the ligand-receptor complex in which both ligand and receptor 
are flexible the induced-fit process is performed using molecular dynamics (MD) simulation. 
The descriptors are the energies of the interaction responsible for the binding between the 
analogue molecules and the receptor [22]. An example of a successful application of the RD-
4D-QSAR approach is the study of 4-hydroxy-5,6-dihydropyrone inhibitors of HIV-1 
protease [23], which permitted prediction of the "bioactive" conformations of the docked 
analogues into the active site of HIV-1 protease close to those found by XRD. Moreover, the 
requirements of specific interactions (hydrophobic, steric and hydrogen bonding) between 
the enzyme active site and the binding site of analogues of 4-hydroxy-5,6-dihydropyrone 
inhibitor  with HIV-1 protease,  indicate directions of development of new lead HIV-1 
protease inhibitors [23].  
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In RI-QSAR, the geometry of the receptor is not available, or it is neglected because it is not 
credible or its binding with ligand is not recognised. This group of methods include the 
"classical" (zero-dimensional), one-dimensional (1D), two-dimensional (2D), three-
dimensional (3D), and four dimensional (4D) QSAR approaches [24]. The calculated 
descriptors are atom and molecular counts, molecular weight, sum of atomic properties (0D-
QSAR); fragment counts (1D-QSAR); topological descriptors (2D-QSAR); geometrical, 
atomic coordinates, or energy grid descriptors (3D-QSAR); and a combination of atomic 
coordinates and sampling of conformations (RI-4D-QSAR) [24]. Commercial drugs 
developed with the aid of classical QSAR include: Norfloxacin (broad-spectrum 
antibacterial agent) Kyorin 1983; Metconazole (Wheat Fungicide),  Kureha 1994; Lomerizine 
(Antimigrane, Antiglaucoma) Organon Japan-Upjohn 1999; Flobufen (Long-acting 
Antiinflammatory) Kuchar et al., Virbac 2000 [25]. 3D QSAR approaches CoMFA [26] and its 
extension CoMSIA [26] are popular thanks to their ability to generate highly predictive and 
easy interpretable models even for flexible molecules, despite the fact that only one 
conformation of each compound is considered. The CoMFA approach uses in its standard 
implementation only Lennard-Jones and Coulomb potentials, while in the extended version 
also the hydrophobic and hydrogen-bond fields are taken into account [27]. The field type 
used in CoMSIA is similar. Instead of field descriptors based on potentials, the use is made 
of the so-called similarity index describing steric, electrostatic, and hydrophobic similarity 
or dissimilarity of molecules. Additionally in CoMSIA, Gaussian-type functionals 
eliminating singularities at the atomic positions are applied [28-30]. Successful application of 
CoMFA is illustrated by the studies of inhibitors: trypsin, thrombin, factor Xa [30] or 
thermolysin [31]. Currently, one of the most advanced QSAR-related techniques is the 4D-
QSAR approach [32] which eliminates the restriction to a single conformation and allows 
averaging of the conventional 3D-QSAR descriptors thanks to the assumed conformational 
flexibility. It allows consideration of the effects of multiple conformations, alignments, and 
substructure groups i.e. extension of 'QSAR degrees of freedom' in comparison to those 
used in 3D-QSAR analysis. In this kind of approach, the so-called grid cell occupancy 
descriptors are used i.e. the occupancy frequencies of the different atom types (any type, 
nonpolar, polar-positive charge, polar-negative charge, hydrogen bond acceptor, hydrogen 
bond donor and aromatic) in the cubic grid cells [33,34]. An example of successful 
application of the RI-4D-QSAR approach is the study of 5’-arylthiourea thymidine 
analogues, showing inhibitory activity against thymidine monophosphate kinase from M. 
tuberculsosis (TMPKmt) [35]. Recently, different RI- and RD-4D-QSAR approaches were 
successfully applied to a variety of enzyme inhibitors of different drug targets, such as HIV-
1 protease [36,37], HIV-1 integrase [38], p38-mitogen-activated protein kinase (p38-MAPK) 
[39], 14-ǂ-lanosterol demethylase (CYP51) [40], enoyl-ACP reductase from M. tuberculosis 
(InhA) [41] etc.  
Construction of a model requires determination of the structural elements of the target that 
would be necessary for the ligand to get recognised and to form a stable active complex. 
Depending on the availability of experimental data, one or a combination of the above 
mentioned methods is used. The optimum situation for CADD application is when both a 
group of ligands of defined activity and the spatial structure of the target are known.  The 
search stage called molecular docking  in which a ligand is matched to the receptor site and 
the quality of the fit (most often expressed in energy) is evaluated, is actually very similar 
irrespective of whether a direct or indirect approach is used. In both cases it is based on 
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algorithms which simulate the docking process of ligands to the target [42]. The receptor 
binding pocket or its homology model can be used with auto-docking to find the most 
appropriate ligands or alternatively 3D-pharmacophore can be used in conformationally 
flexible (steric interactions) search for ligands that fit to the spatial distribution of the 
receptor. In order for the ligand-target interaction to occur, a few conditions must be met, 
such as a sufficient concentration of the drug which depends on the quantity of drug 
administered, its capacity to reach the target and its affinity and specificity for the target. 
Only specificity and affinity can be modelled, because they are directly related to the 
structural and electronic complementarities of the drug and target. The structural 
complementarity is strictly mechanistic and can be described as hollow/bump or key/lock 
adjustment. It is facilitated by the flexibility of drug and target i.e. their susceptibility to 
conformational changes which ensure the mutual compatibility of these two molecules. The 
electronic complementarity can be described as attraction/repulsion depending on the 
mutual relation between electron densities of the drug and target. In general it facilitates the 
approach of the drug to its target and in a consequence its binding. The most desirable 
combination is both a structural complementarity and an electronic complementarity 
between drug and target, as it ensures the best affinity. The interaction established between 
drug and target stabilizing the complex is rarely covalent and typically of low energy 
(electrostatic, van der Waals, hydrogen bonding). Therefore docking is accomplished by 
either geometric matching of the ligand and its receptor (faster) or by minimising the energy 
of interaction (slower, more accurate). Geometric matching is often replaced by the 
matching based on charge distribution, bond vectors, conformational flexibility, 
hydrophobic properties or molecular fragments.  
Thus the knowledge of the 3D structure and/or the physico-chemical properties (electronic, 
steric, hydrophobic features etc.) of the drug and its biological target as well as the 
knowledge of their fluctuations related to their molecular motions, polymorphic transitions 
or shifts in tautomeric equilibrium of drug, is fundamental to understanding molecular 
recognition and intermolecular interactions participating in drug-target binding.  
Many experimental and theoretical, very sophisticated techniques, provide complementary 
types of data, which after quick selection are considered to be required or not for the full 
description or prediction of drug - target interaction. With the development of experimental 
(e.g. XRD, NMR, NQR) and theoretical methods (e.g. ab initio, DFT at different levels) not 
only the number of recognised 3D structures of ligands and targets has dramatically 
increased, but also the amount of information on structural dynamics and electronic 
properties of drugs. The increased availability of these data is crucial for rational drug 
design, which in general has to involve many different pathways to achieve one common 
goal that is a drug more efficient and selective to its therapeutic target which exhibits 
efficacy in vivo and shows low toxicity. Achievement of this goal does not seem possible 
without understanding drugs on the molecular level. 
3. Understanding of drugs on the molecular level 
From the chemical point of view, the most important components of drugs i.e. Active 
Pharmaceutical Ingredients (API), a substance of a drug which is biologically active, and 
excipients, inactive substances used as a carrier for the API,  are composed of small, organic, 
low-weight molecules (molecular mass below 100 Da, only rarely 500 Da) mainly obtained 
through chemical synthesis. However, the interest in drugs available through biological 
www.intechopen.com
 
Towards Understanding Drugs on the Molecular Level to Design Drugs of Desired Profiles 
 
237 
processes (biopolymer-based) steadily increases. It is difficult even to estimate the total 
number of currently known drugs and targets, as it is continuously in change, the data are 
scattered over multiple resources and available in a non-uniform manner. Comprehensive 
Medicinal Chemistry (CMC) lists 8,659 [43], PharmaPendium covers over 4,000 [44], 
Thomson REUTERS Forecast [45] tracks approximately 3,500 in clinical-stage and marketed 
drugs (700 strategic drugs). One of the largest databases – the Therapeutic Target Database 
[46] contains information about 11,978 drugs (including 1,514 approved, 1,282 in clinical 
trial, 9,182 experimental drugs and 3,645 multi-target agents) covering 140 therapeutic 
classes and 1,973 targets (including 358 successful, 254 clinical trial, 44 discontinued and 
1,317 research targets) covering 61 protein biochemical class. Another database, BindingDB, 
contains 316,172 small drug-like molecules and 721,721 measured binding affinities for 6,179 
protein considered to be drug-targets [47]. The DrugBank database [48] – a unique resource 
that combines chemical, pharmacological and pharmaceutical data with drug target (i.e. 
sequence, structure, and pathway) contains 6,816 drug entries including 1,437 FDA-
approved small molecule drugs, 134 FDA-approved biotech (protein/peptide) drugs, 83 
nutraceuticals and 5,194 experimental drugs. 
According to World Health Organization (WHO) reports [49] the number of essential drugs 
has nearly doubled, from 186 in 1977 (1st edition) to 364 in 2011 (17th edition). It should be 
remembered that the list of essential drugs is extremely selective and includes only "those 
drugs that satisfy the health care needs of the majority of the population; they should therefore be 
available at all times in adequate amounts and in appropriate dosage forms, at a price the community 
can afford" [50]. The US Food and Drug Administration (FDA) agency lists about 800 
approved API and there are over 100,000 drug products created from those API collected in 
Green Book, while 14,309 (primarily small-molecule drugs) are collected in US FDA's 
Orange Book [51] and about 6,000 biological drugs are listed by the Centre for Biologics 
Evaluation and Research (CBER) [52]. However, when duplicate APIs, salt forms, 
supplements, vitamins, imaging agents etc. are removed, the list of unique drugs can be 
shortened to 1,357, of which 1,204 are 'small-molecule drugs' and 166 are 'biological' drugs. 
FDA list contains also 11,066 inactive ingredients i.e. excipients.  
The widely used classification system for API substances is the Anatomical Therapeutic 
Chemical (ATC) system [53] introduced in 1976 and controlled by Collaborating Centre for 
Drug Statistics Methodology (WHOCC). ATC categorizes API at different levels: anatomy, 
therapeutic properties and chemical properties according to therapeutic aspects. The 
modern, very recently introduced, system of classification [54] assumes that all current 
drugs with a known mode-of-action act through 324 distinct molecular drug targets and 
classifies them according to known targets (biochemical structures like: enzymes, substrates, 
metabolites and proteins, receptors, ion channels, transport proteins, DNA/RNA and the 
ribosome, targets of monoclonal antibodies; various physicochemical mechanisms and 
unknown mechanism of action). Current therapy is based on the above mentioned 
molecular targets [55,56] of which 270 are encoded by the human genome (45% - G-protein 
coupled receptors, 28% - enzymes, 11% - hormones, 5% - ion channels and 2% - nuclear 
receptors). Because each of 10 genes which contribute to multifactorial diseases are typically 
linked to other 5 - 10 gene products in physiological circuits suitable for pharmaceutical 
intervention, it is expected that in fact there are at least 10-20 times more targets [57]. Their 
identification is a priority as it determines the discovery of innovative drugs.  
Many API's are intended to be used in solid dosage formulations, which is generally 
preferred for oral route of administration due to greater stability, smaller volume, accurate 
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and flexible dosage and easy manufacturing. In fact oral small-molecule API's target as 
many as 227 molecular targets [56]. The modern system of classification of APIs according to 
known targets in fact classifies them according to their mechanisms of action i.e. the API 
effect at the molecular level. Understanding the API effect at the molecular level requires the 
knowledge of fundamental data including spatial 3D structure and physico-chemical 
properties of API. A combination of the experimental (XRD, NMR, NQR  spectroscopic 
techniques) and theoretical data (ab initio, DFT calculations) in a synergistic manner not 
only provides the data on structure or properties but also allows prediction of the way in 
which the specific molecular changes will alter the features of API. This, in turn, indicates 
the directions of design of new API by taking into account such factors as predisposition to 
participate in certain intermolecular and intramolecular interactions, tendency to 
polymorphic or tautomeric transitions, required stability (thermal or photo or radiation 
stability) or solubility. All these factors are closely related to biological effect therapeutic or 
toxic thus provide the basis for understanding drugs at a more fundamental level. The 
examples discussed in the next section will cover some, but not all these aspects. 
3.1 Spatial 3D structure  
In 1868 Brown and Fraser [58] discovered that biological activity of compounds is related to 
their chemical structure. Until the mid 1990s, the 3D structure was in fact the main a basis of 
drug design, but even nowadays it is still a key factor. As previously mentioned, the 
knowledge of the spatial 3D structure of API itself or its biological target is the core of 
CADD techniques. 3D structure of API or target can be determined either experimentally, 
using direct or indirect methods, or can be predicted theoretically.  
3.1.1 Experimental structure 
XRD 
The most important sources of information on the drug structures are direct crystallographic 
methods, i.e. the methods which derive diffraction phases directly from experimentally 
measured diffraction amplitudes. The first atomic-resolution crystal structure solved by 
Bragg in 1914 [59] was that of NaCl - a substance playing a crucial role in maintaining the 
fluid and electrolyte balance. The standard single crystal XRD, actually providing a 
resolution of 0.5-3.0 Ǻ, is a main source of information about the molecular conformation 
and packing in the crystalline structure. For  small molecules, the crystal structures are 
usually well resolved. However, high quality single crystals of sufficient size of many 
pharmaceuticals have proved impossible to grow, while polycrystalline powders can be 
readily made. For such substances, the powder X-ray diffraction (PXRD) or small-angle X-
ray scattering (SAXS) are used to obtain the relevant structural information, which is in fact 
less detailed. Despite this, PXRD pattern, considered as a characteristic fingerprint of a 
crystalline phase, is used to identify and characterise crystal forms including polymorphs 
(1800 of such a patterns are stored at CSD).  
A significant disadvantage of XRD from the point of view of APIs studies is not only the 
necessity of obtaining crystals, but the difficulty in determining the positions of light atoms 
such hydrogen (only one electron) resulting in imprecise description of weak intermolecular 
interactions. Although, various parameters describing the covalent geometry (i.e., bond 
lengths, bond angles, planes, and chirality) are determined to a very high accuracy [60], the 
degree of uncertainty of the parameters characterising the weak, nonbonding interactions is 
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still high. The application of neutron diffraction (ND), which due to the interaction of 
radiation with atomic nuclei gives highly accurate positions of tiny atoms (hydrogen), 
partially solves this problem. The widely used approach for this purpose is the Hansen–
Coppens formalism [61] in which individual atomic densities are described in terms of a 
spherical core and valence densities. Expansion of the atom-centred spherical-harmonic 
functions is the main idea of this so-called multipole approach. Another solution is 
modelling with the use of independent atoms [62], or partial optimisation using quantum 
chemistry methods ab initio or DFT [63]. However, irrespective of the method, the final 
result becomes in fact not purely experimental. The most accurate API structures, with 
respect to both molecular geometry and motional description, still come from low-
temperature ND [64]. Despite the above mentioned inconveniences, XRD is the starting 
point for gathering information about APIs.  
XRD is also the oldest and major source of 3D structures of targets as well as drug-target 
complexes [65,66]. In 1965 Johnson and Philips [65] solved the structure of lysozyme (with 2 
Å resolution), a 14,7 kDa enzyme which can be found in tears, saliva and egg white. A 
milestone in the development of CADD was the invention of X-ray structural analysis 
techniques that would allow examination of structures of very large molecules - proteins, 
enzymes. The largest known and resolved by XRD protein is human Titin, which consists of 
34,350 amino acids, with the molecular weight of the 'canonical' isoform of the protein being 
approximately 3,816,188.13 Da [67]. However, its use is still marred with a number of 
restrictions, the method can be applied to good crystals, so its use is restricted to solids 
(difficult to obtain for targets), it gives no possibility to examine small parts in the large 
molecule in details, it is unable to reveal many conformations (molecular motions are 
neglected) or to determine the secondary structures, which is crucial for the target or drug-
target complex. A common but rarely mentioned problem of X-ray crystallography and 
electron crystallography is radiation damage of the samples studied. 
The other worth mentioning techniques, complementary to XRD, are the Small-angle X-ray 
scattering (SAXS) [68], atomic forces microscopy (ATF) [69] or cryo-electron microscopy 
[70], which allow studies under physiological conditions and are used for studies of micro 
or nanoscale particles. However, actually their resolution is still lower than that of XRD. One 
more technique complementary to XRD is the high-resolution electron microscopy (HREM), 
which can be successfully applied for crystal structure analysis when the grain size is too 
small or periodicity is imperfect. Its main advantage over XRD is more convenient 
observation of light atoms in the presence of much heavier atoms. HREM is able to produce 
a microscopic image and a corresponding diffraction pattern in the atomic scale, however, 
for crystalline samples the resolution is too low to reveal individual atoms [70]. 
There are many other techniques that are useful in the study of crystals, but their description 
is outside the scope of this paper. 
NMR 
Some of the limitations of XRD can be easily overcome by other techniques like NMR, which 
reveals a 3D structure of a molecule not only in crystal but also in its natural - biological 
environment. Solid state NMR (SS NMR) is one of the most important tools for structural 
investigation of solid APIs for which it delivers data complementary to XRD (precise bond 
lengths and angles within a molecule, intermolecular bond lengths and angles). It can be 
said that it adds the time-dependence to the XRD parameter-set, which allows studies of the 
kinetics of reactions, molecular motions, conformational changes etc. Depending on the type 
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of experiment, different NMR parameters: isotropic chemical shifts, coupling constants, rate 
constants, chemical shift tensors, spin diffusion and dipolar interactions etc., provide 
different information about the chemical environment of the selected nuclei in a molecule. In 
general, the principles are the same for solution and SS NMR. However, low sensitivity and 
severe line broadening originating from chemical shift anisotropy (CSA) and dipolar 
interactions are serious inconveniences for SS NMR. Three techniques: cross polarisation 
(CP), magic angle spinning (MAS) and high-power1H decoupling are applied to overcome 
the problems encountered in the solid state NMR. For small compounds like APIs each 
chemically inequivalent site and functional group can be distinguished on the basis of 
chemical shift. In fact, unique SS NMR spectroscopy capabilities allow differentiation of 
isomorphic solids, which are difficult to distinguish by XRD. When the spectra are 
complicated, the spin-spin splittings or J-couplings are used to elucidate and verify a 
possible structure but this can prove insufficient [71]. Moreover, in large molecules such as 
e.g. targets, the number of chemical shifts can be extremely large (even several thousand) 
and can suffer from incidental overlaps. The use of sophisticated techniques like 
multidimentional 2D-4D NMR is then required [72-76]. The most popular are 2D 
homonuclear NMR experiments: correlation spectroscopy (COSY) [71] and total correlation 
spectroscopy (TOCSY) [72], which correlate different spins via scalar spin–spin couplings or 
nuclear Overhauser effect spectroscopy (NOESY) [73], which describes dipole–dipole 
coupling between pairs of nuclei or Incredible Natural Abundance Double Quantum 
Transfer Experiment (INADEQUATE) [77], which correlates different carbon nuclei. Each of 
them produces two-dimensional spectra mapping chemical shifts and reflecting adjacent 
atoms (COSY) or all atoms if they are connected by a continuous chain of protons (e.g. side 
chains of amino acids) (TOCSY). Apart from this, the method is also able to reveal the 
spatial proximity between the atoms (NOESY). As the intensity of a NOESY peak is 
reciprocally proportional to the 6th power distance, thus it reveals the distance. Because the 
intensity-distance relationship is approximate thus NOESY derived distance is not exact. 
The other disadvantages of NOESY are separations no farther than 5 Å and the ambiguous 
assignment of peaks that are close in space but do not belong to the sequential residues. For 
such a purpose the technique of labelling of proteins (with 13C, 15N or 2D) is used. Instead of 
NOESY one or more of the six HSQC-type experiments (HNCO, HNCACO, HNCA, 
HNCOCA, HNCACB and CBCACONH) can be used, which are capable to resolve overlap 
in the carbon dimension. The most widely used is the HCCH-TOCSY method (i.e. TOCSY 
resolved in an additional carbon dimension). Apart from distances, NMR provides 
estimation of the torsion angles (on the basis of J-coupling constants - Karplus equation or 
chemical shifts). The introduction of isotope labelling and multidimentional experiments 
extended the area of NMR applications to targets. However, fast relaxation and broader and 
weaker peaks, which can easily disappear are important limitations. Recently, two 
techniques dedicated to large target studies have been introduced: residual dipolar 
couplings (RDC) [78,79], which can be used in particular for the reveal the orientation of the 
N-H as well as the whole structure refinement, transverse relaxation optimised spectroscopy 
(TROSY) [80,81] and cross-correlated relaxation-enhanced polarisation transfer (CRINEPT) 
[82]. These modern techniques allow studies of targets larger than 150kDa. It should be 
emphasised that the structural information provided by NMR is indirect because no simple 
relationship between the experimental data and Cartesian coordinates is available. While 
XRD delivers the approximated coordinates of atoms in target, the NMR gives the 
estimations of distances between the pairs of target atoms. Therefore, the final conformation 
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of a target is obtained, by solving a geometry-distance problem. Because the actual 
conformation depends on the properties of the environment, thus the use of NMR to study 
its influence is possible, for example the influence of different solvents. The resolution of 
NMR, 2-5 Å, is much lower than XRD since the information got from the same material is 
much more complex. For the same reason, NMR allows determination of the 3D structure of 
smaller molecules than XRD. The most spectacular NMR result is the determination of the 
protein in complex with the 900 kDa chaperone GroES-GroEL [83]. Unique advantages of 
NMR are the capability of solving secondary structures [84-86] and mapping the binding 
sites of the substrate [87,88]. At the current state-of-the art methodologies, XDR is still much 
more efficient than NMR, even in solving a structure of a target. While NMR is expensive - 
requires isotope labelling, sophisticated spectrometers and time consuming - a 
determination a high-resolution structure of proteins <40 kDa may take even a year, XDR 
routinely solves it in weeks to months. Despite these limitations, the role of NMR is 
continually expanding, as evidenced by the fact that NMR has evolved into one of the two 
major techniques for elucidation of structure and dynamics of targets and target-drug 
complexes.  
Taking into account advantages and disadvantages of both methods the optimum method 
for solving structure of API is XRD, while a combination of XRD and NMR studies provides 
3D structures of targets or drug-target complexes.  
Against the background of the above mentioned methods, NQR, which gives quadrupole 
coupling constants (e2qQ/h) and asymmetry parameters () from experimental frequencies, 
seems to have very limited capabilities. Moreover its use involves a number of restrictions; it 
can be applied only to high purity solids (crystalline or polycrystalline), only for selected 
isotopes and practically its applications are limited to API. In fact, however, this 
underappreciated technique has some unique advantages and is an effective tool for 
preliminary study of crystal structure in the absence of X-Ray data.  It allows measurements 
of distances but only NH or OH bond lengths, gives the number of inequivalent molecules 
in the elementary cell, permits differentiation of isomers, enantiomers, polymorphs etc.  
Successful application of NQR to analysis of structural aspects is illustrated by the studies of 
the most widely used cytotoxic agent most effective in the treatment of epithelial 
malignancies such as lung, head and neck, ovarian, bladder and testicular cancer, 
i.e.cisplatin cis -diamminedichloroplatinum (II).  Although cisplatinum and its complexes 
are widely used as anti-cancer drugs, neither its isomer – transplatin trans -
diamminedichloroplatinum (I) – nor its complexes have therapeutic properties. Possible 
explanations of different biological activity of the cis and trans isomers are that cis 
compounds make platinum-DNA adducts inhibiting DNA replication or transcription to a 
greater extent than those formed by transplatin, and alternatively, that DNA adducts 
formed by trans compounds may be repaired more efficiently [89]. Thus, differentiation 
between the cis and trans isomers is essential. Isomers distinction for any platinum 
compounds showing trans – cis isomerism with 35Cl-NQR is easy as the difference in the 
resonance frequencies is high enough and reaches 2.13 MHz: 16.18 MHz for cis-platinum 
and 18.31MHz for trans-platinum [90]. Another interesting example of NQR capabilities is 
the study of serine, which occurs in the active sites of many enzymes like chymotrypsin, 
trypsin and plays an important catalytic function. The enzyme serine racemase converts L-
serine into the less common D-isomer (a co-agonist of the N-methyl-D-aspartate receptor in 
glutamate neurotransmission) and can be used to develop treatments for neurodegenerative 
diseases (schizophrenia). The sophisticated high sensitivity SQUID technique allows studies  
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of chirality i.e. distinction of L-serine and D-serine and its racemate DL-serine [91] on the 
basis of small differences in the frequencies (0.018 and 0.023 MHz), quadrupole coupling 
constants (0.004 MHz) and asymmetry parameters (0.066 MHz). One more illustrative 
example are NQR studies of diuretic drugs: the highly active and thus widely used one -
hydrochlorothiazide (HCTZ) and the weak one and thus used only to alter the mode of 
furosemide activity - chlorothiazide (CTZ). Both are used in the treatment of hypertension, 
congestive heart failure, symptomatic oedema and prevention of kidney stones. The 
difference is only in one bond (in CTZ either the bond N(2)–C(3) or C(3)–N(4) is double, 
while in HCTZ one hydrogen atom occurs at N(2) and N(4), and the two bonds N(2)–C(3) 
and C(3)–N(4) are single). This structural difference results in a significant (1.26 MHz) 
difference in frequencies, which makes the distinction of both compounds very easy [92].  
As far as large structures are concerned, a striking example of NQR application was a direct 
observation of Zn2+ in Carbonic Anhydrase (CA), the first enzyme whose activity was 
recognised to be related to the presence of Zn2+, which was postulated as the activator of 
bound H2O. CA, which commonly occurs in all mammalian tissues, plants, algae, and 
bacteria, is perhaps one of the best recognised metalloprotein. The 67Zn QCC values, being 
sensitive to changes in the structure and bonding associated with water or hydroxide have 
been found independent of pH over the range of 5 to 8.5 [93], whereas, according to the 
hitherto commonly assumed model, Zn2+ should be coordinated by H2O, and as a result, at 
these pH values the 67Zn NQR spectrum should be three to five times broader than that at 
pH 8.5. This observation was in contradiction to the widely accepted mechanism and led to 
acceptance of an alternative one proposed by Merz, Hoffmann, and Dewar [94]. The above 
example demonstrates the significance of zinc NQR spectroscopy in delineating the 
structure and mechanism of activity of this class of metalloproteins.  
These examples show that NQR has a potential to provide vital structural information about 
the drug, target and the drug-target interaction.   
3.1.2 Predicted structure 
Prediction of the structure of single molecules, the so-called geometry optimisation, is 
available within different approaches starting from molecular mechanics up to very 
sophisticated levels of the quantum chemical theory. But a single molecule structure is far 
from that in crystal, especially for flexible molecules. Although it is known that molecules in 
crystals are bonded via intermolecular interactions, which are weak and numerous, but they 
act at long ranges and have little directionality, which makes crystals difficult to model [95]. 
Thus crystal structure prediction (CSP), which includes the prediction of the crystal 
structures of solids from first principles, is a much more complicated task. Reliable methods 
for the prediction of crystal structure only on the basis of molecular structure have been 
searched for since the 1950s [95]. Until recently, crystal structure could not have been 
predicted computationally from first principles because of the nature of forces acting 
between the molecules in crystals. Reliable CSP requires assumption of clearly defined 
criteria of the quality of structure reproduction. One possibility is a comparison of  the 
predicted structure with those experimentally determined. A good test of CSP quality is the 
validity of reproducing structures that differ only slightly as those of different polymorphs. 
Indeed, many unsuccessful attempts to predict the structures of polymorphs of 
sulphonamide have been undertaken. It was believed that the reason for the failure was the 
kinetic nature of crystallization. But it turned out that successful CSP for small drug 
molecules is possible [96,97]. Only recently, the structures of three known polymorphs of 
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sulphanilamide have been correctly predicted from ab initio [98]. The prediction of target or 
target-drug structure is still an issue for the future.  
Much faster is the CSP validation based on experimental parameters. For example NQR, 
which is a very sensitive technique, provides parameters directly describing the local 
environment of a nucleus in the molecule. However CPS, based only on these data is 
impossible, but in combination with DFT it can be used for example to evaluate the degree 
of structural refinement. A valuable example is triclosan (5-chloro-2-(2’,4’-dichlorophenoxy)-
phenol, TCS) active pharmaceutical ingredient (API) of a known potent wide spectrum of 
antibacterial, antimicrobial and antifungal agents used in many drugs as well as antiseptic 
or disinfectant formulations. The crystalline structure of TCS, which  crystallizes in the space 
group P31 with one molecule in the asymmetric unit has been solved by XRD and refined to 
a final R-factor of 2.81% at room temperature [99] and 3.74% at 90 K [100]. The conformation 
adopted by diphenyl ether of TCS in solid is temperature independent, typical of diphenyl 
ethers but the opposite to that adopted when it is bound to different inhibitors. The 
importance of this finding is the suggestion of the presence of two enantiomers of triclosan, 
which would nicely explain a wide spectrum of its activity. The smooth changes in NQR 
frequency with temperature increasing from 77 K to 300 K [101] and similar parameters of 
the unit cells at RT and at 90 K (a=12.5225 Å, b=12.5225 Å and c=6.6809 Å [100] versus 
a=12.6410 Å, b=12.6410 Å and c=6.7163 Å [99]) confirmed no phase transformation from RT 
to 90 K during the data collection. The differences in RT and 90K structures seem relatively 
small but the NQR spectrum of triclosan was much better reproduced at the  
B3LYP/6-311++G(d,p) level of theory assuming the room temperature structure than 90K 
one. The scattering of NQR frequencies was found to be a good indicator of the quality of 
the crystallographic structure resolution [99].  
 
 
Fig. 1. Predicted structure of sulfamethizole. 
NQR combined with DFT can be also used for structure prediction. An interesting example 
is the structure of sulfamethizole, known to be able to crystallize in different polymorphic 
forms [102,103] of which none, even the most stable one, was solved. In a single molecule of 
sulfamethizole there are four nonequivalent nitrogen positions, but within the NQR 
experimental resolution five nitrogen positions have been detected [104]. This indicated 
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either two nonequivalent molecules in the unit cell or two polymorphic crystal forms of 
sulfamethizole. The lines at the–NH- and –NH2 nitrogen positions do not show any splitting 
within the experimental resolution. A possible explanation of the 14N NQR spectra is that 
the sulfamethizole molecules form slightly asymmetric hydrogen bonded pairs, similar to 
the symmetric pairs formed by the acetazolamide molecules. The NQR parameters obtained 
by B3LYP/6-311++G(d,p) assuming putative dimeric structure, Fig.1., were in a very good 
agreement with the experimental data [104].  
Studies of isostructurality and annular 50:50 prototropic tautomerism of 
pentabromobenzimidazoles make another example of the successful prediction of crystalline 
structure performed by NQR and DFT/QTAIM combined [105]. On the basis of three 
known XRD structures of 4,5,6,7-tetraiodo-1H-benzimidazole, 4,6-dibromo-5,7-diiodo-1H-
benzimidazole and 4,6-dichloro-5,7-diiodo-1H-benzimidazole the crystalline structures of a 
set of pentabromo-benzimidazoles have been proposed and the most stable polymorphic 
form (alpha) has been predicted. 
3.2 Intermolecular interactions pattern  
Intermolecular interaction pattern can be analysed using structural data, but more detailed 
information can be derived from the electron density distribution, which can be determined 
either experimentally or theoretically. The electron density distribution is a purely physical 
property of molecules and an observable, thus it can be approached experimentally directly 
(as maps) or indirectly (as parameters).  
For single molecules electron density distribution can be derived from gas electron 
diffraction (GES) while for solid formulations of drugs from diffraction methods like XRD or  
neutron diffraction. Using the intensities (measured directly) and phases of the scattered X-
Rays (obtained indirectly for example by intelligent guess i.e. Hautpmann-Karl method, 
through isomorphic substitution or a comparison of intensities at a range of wavelengths 
near the K edge of a heavy atom in the crystal) the electron distribution in the crystal after 
3D Fourier transform can be mapped as a contour plot, the so-called Fourier map of electron 
density. According to Parseval's theorem [106], the rms error in Fourier map is proportional 
to the rms error in the structure factor thus minimisation of rms error in electron density 
distributions ensures getting a structural factor that minimises the rms error in the complex 
plane. Importantly, X-ray is in fact an imaging technique because the Fourier transform of 
the observed structure yields an electron density map of the molecule.  
SS NMR, which is complementary to XRD taking into account structure solving, does not 
deliver an electron density distribution per se but the variations in chemical shielding (or its 
isotropic chemical shifts) that reflect the variations in this distribution (lower electron 
density is reflected by smaller chemical shifts). The reliable and experimental parameters 
directly describing electron density distribution - quadrupole coupling constants and 
asymmetry parameters - are delivered by NQR. They reflect the electron distribution in the 
vicinity of the quadrupolar nucleus, thus provide a very sensitive tool for investigation of 
short range interactions (in contrast to the long range periodic order seen by the XRD). The 
disadvantage of NQR is the fact that it is not an imaging technique i.e. it does not deliver 
Fourier maps.  
The electron density distribution can be also obtained theoretically using quantum chemical 
calculations at  different levels of theory (semiempirical, ab intio or DFT).  
Detailed analysis of topology of the electron density distribution, obtained experimentally 
or theoretically, can be performed within the Quantum Theory of Atoms in Molecules, 
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QTAIM formulated by Bader [107]. Within this approach the electron density (r) of a 
molecule, treated as a scalar field, can be examined by analysis of its gradient vector field 
and a Laplacian. An atom is defined as a region of real space bounded by surfaces through 
which there is a zero flux in the gradient vector field of the electron density. The values of 
(r) at the start and end points of a gradient path, which follows the largest increase in (r), 
take extremes: maxima or minima, or saddle points in the electron density. Depending on 
the nature of the extreme they are called the nuclear attractor-, bond-, ring-, and cage- 
critical points and denoted as NACP, BCP, RCP and CCP, respectively. The type of the 
critical point can be easily determined with the help of a Hessian matrix composed of nine 
second-order derivatives of (r). The knowledge of electron density distribution allows  
evaluation of many one-electron properties (e.g. electric dipole moment, electrostatic 
potential, electric field, electric field gradient, Laplacian of electron density, molecular 
orbitals) describing the bonds in molecules and intermolecular interactions pattern in 
molecular crystals. The electron density (r) at BCP and its Laplacian are the indicators of 
the character of the bond and allow classification of the bondings according to the following 
rules: 
 ǒ(r) > 0, ǒ(r) < 0; covalent (pure closed-shell) 
 ǒ(r) ~0, ǒ(r) > 0; ionic (pure shared shell) 
 ǒ(r) > 0, ǒ(r) > 0; charge shift (transit closed shell)  
A number of books [107,108] and review articles [109-111] have described this technique and 
given examples of its application. The electron density (and thus properties of a molecule) 
varies according to the local geometry (binding partners, bond lengths, angles between 
bonds etc.) or external factors (temperature, pressure, solvent, external electric field etc.). 
Additionally, the electron density can be also influenced by another molecule to the extent 
dependent on polarisability. This factor is very important for slightly charged atoms having 
a great number of electrons, like sulphur or iodine, which permits their participation 
in intermolecular interactions.  
Highlighted below are the examples wherein SS NMR and especially NQR spectroscopy 
combined with DFT has been used to extract detail information on APIs. In this section, 
particular instances of application of NQR spectroscopy, which provide unique quality 
information for CADD i.e. for crystal engineering strategies and structure-property 
relationships are presented. 
3.2.1 Polymorphism 
Polymorphism (Greek: polys -multiple, morfé - shape) is the ability of a substance to exist in 
more than one crystalline form (polymorph) depending on the crystallisation conditions. 
While initially most polymorphs have been discovered by chance [111-115], recently 
identification of polymorphism is a result of a systematic search or is even required by the 
FDA standards. According to McCrone suggestion, "in general, the number of forms known for a 
given compound is proportional to the time and money spent in research on that compound" [116]. 
Approximately 70% of API exhibit polymorphism and rarely the differences between two 
polymorphs and their properties are subtle (e.g. aspirin - acetylsalycilic acid [117]). 
Polymorphs differ in physico-chemical properties (e.g. solubility, dissolution rate, 
permeability, chemical reactivity, melting point, optical and electrical properties, vapour 
pressure, crystal shape, compressibility, density, hardness, resistance to degradation), which 
makes a very important problem from the point of view of pharmaceutical industry. It can 
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cause crucial problems not only with the manufacturing or the quality of the formulation 
but also with the biodisponibility of the active substance and drug stability (i.e. shelf life of a 
drug). Thus characterisation of solid-state properties of API as well as excipients is of 
particular interest. In fact API exhibiting structural polymorphism received regulatory 
approval for only one single crystal form or a specific polymorph. An example is Cefdinir, 
broad-spectrum antibiotic, for which a lot of companies (Fujisawa, Biochemie, ACS Dobfar, 
Orchid, Abbott, Aurobindo, Novartis, Lupin, Rambaxy) patented 11 polymorphs related to 
5 crystalline forms [118], atorvastatin calcium - a statin lowering blood cholesterol, for which 
more than 60 solid forms have been patented [119], piroxicam - a non-steroidal anti-
inflammatory drug, synthesized in more than 50 forms [120] and sulfathiazole a local 
antimicrobial agent for which more than 100 forms have been described [121]. From among 
multicomponents the one showing the optimum properties from the biological activity point 
of view is chosen. 
For pharmaceutical companies, the phenomenon of polymorphism is rather a disadvantage, 
however sometimes it is used to extend original patents on existing API ,but this procedure 
requires checking that one polymorph does not decompose or transform to another 
(infringement of another patent). A well-known example is the patent litigation between 
pharmaceutical companies Glaxo and Novopharm concerning two polymorphs of ranitidine 
hydrochloride – a histamine H2-receptor antagonist that inhibits stomach acid production 
[122], the problem of "disappearing polymorphs" of ritonavir [123] – an inhibitor of HIV-
protease manufactured by Abbot Laboratories or paxil - anti-depressant manufactured by 
SmithKline Beecham (GlaxoSmithKline). Therefore, the original companies use a stable 
polymorph, while the generic companies a meta-stable polymorph. The way of labelling of 
polymorphs is inconsistent (e.g. I, II, III …; A, B, C…; ǂ,ǃ,Ǆ...) and has no relation to a 
polymorph stability; it occasionally happens that identical forms are named differently. 
In general, polymorphism results from different crystal packing of rigid molecules (packing 
polymorphism) e.g. acetazolamide, cloxiquine, the presence of different conformations of a 
flexible molecule (conformational polymorphism) e.g. sulfanilamide, chlorpropamide, or 
can be a result of inclusion of water or solvent molecules in the lattice i.e. hydration or 
solvation, respectively (pseudopolymorphism or solvatomorphism) e.g. chloral hydrate,  
cefdinir. The packing polymorphism is much rarer than the conformational one. In practice 
usually the mixed types of polymorphism are encountered. The most frequent case is 
dimorphism. There is a tight connection between the synthons arrangement (packing 
polymorphism) or the molecular conformation (conformational polymorphism) and the 
crystal packing in a an elementary unit. The weak noncovalent interactions (hydrogen-
bonds, Van der Waals forces, coulombic interactions, steric repulsions - interactions) are 
responsible for the bonds between molecules or supramolecular synthons in the crystal. In 
general, the molecular energy and the lattice energy of the crystals are not independent, but 
in fact they  control each other. Changes in the weak interaction pattern are able to induce 
further changes for example in torsion angles, which can result in stabilization of different 
molecular conformations close to the most stable equilibrium one. Consequently, various 
nearly energetically equal molecular conformations can force crystallization in different 
polymorphs. Therefore, a study of molecular motions is sometimes used for the 
characterisation of polymorphs. Elucidation of the very origin of polymorphism is often 
crucial to understanding drugs at the molecular level. Polymorphism is a widespread 
phenomenon among small molecules of APIs, mostly because of their flexibility, the 
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presence of hydrogen bond donor/acceptor sites or overlapping of p-orbitals in Ǒ-
conjugated systems. 
The differences in crystalline structures between polymorphs result in differences in their 
properties, of which solubility and dissolution rate are considered to be the most important. 
The solubility in aqueous media is of particular interest because it may influence 
bioavailability. Although a typical ratio of solubility of two polymorphs is less than two, it is 
not a rule. For example the ratio of two polymorphs of acetazolamide (I and II) is 1.11 [124], 
while for premafloxacin (I and III) or chloramphenicol (A and B) it exceeds 10 [125]. When 
the differences between the solubility of polymorphs are great, the minimum therapeutic 
concentration in the blood of the poorer soluble polymorph (according to the Hammond 
rule [126], the poorer soluble polymorph can be more therapeutically active) can be 
insufficient for its effective activity. It is a rule that anhydrates/ansolvates of API are better 
soluble than its hydrated/solvated forms. 
There are a number of methods that can be used to characterise polymorphs of a drug 
substance [127] but the single crystal XRD is currently regarded as bringing definitive 
qualitative and quantitative evidence of polymorphism. Facility of XRD data acquisition and 
XRD usefulness as a screening technique make it is more often used than the other physico-
chemical methods commonly used for the investigation of polymorphism, like hot-stage 
microscopy (melting point), solid-state infrared spectroscopy (IR), X-ray powder diffraction 
(PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), 
differential thermal analysis (DTA), FT-Raman spectroscopy and scanning electron 
microscopy (SEM). However, XRD analysis is not always possible, for example, when no 
single crystal of sufficient size, quality or stability can be obtained. The complementary tools 
of ever-growing value for the solid-state characterisation of API, excipients or drug 
formulations are the solid-state nuclear magnetic resonance spectroscopy (SS NMR) and a 
more sophisticated but less popular - nuclear quadrupole resonance (NQR). As compared to 
the IR, Raman, and XRD techniques, SS NMR or NQR are bulk techniques in which the 
particle size of the substance studied does not matter. In contrast to XRD, they can be 
applied even to amorphous samples (in the case of NQR after freezing in liquid nitrogen), 
although it is not easy because of great line widths. Both techniques are non-invasive and 
non-selective which means that low molecular weight components in the sample can be 
detected in a single experiment. In a sense they can be defined as selective because they 
allow detection of signals from the selected types of nuclei. Both techniques are quantitative, 
i.e. can be used to measure the content of API in a sample. Compared to other techniques, SS 
NMR and even more NQR are less sensitive and require more expensive equipment, which 
is their main drawback. Although in many cases SS NMR or NQR can be very effective, the 
majority of studies of pharmaceutical polymorphs are still performed in conjunction with 
other analytical techniques. While NMR has become in recent years very popular in studies 
of drugs, the use of NQR spectroscopy is rather scarce as from over 250 compounds whose 
polymorphism has been studied by this method [128] fewer than 20 were API, 
pharmaceutical formulations or excipients. 
In general, the suitability of solid-state NMR or NQR for investigation of polymorphism 
follows from the fact that each polymorph is crystallographically different, which means 
that a certain nucleus in each polymorph is in a slightly different local molecular 
environment. Since the local environment at the nucleus site of interest is different, the SS 
NMR or NQR spectra differ slightly. In consequence, the isotropic chemical-shift / CSA 
tensor or NQR frequency/quadrupole coupling constant and asymmetry parameter derived 
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from these spectra also differ for the corresponding sites. Thus the analysis and spectral 
assignment of the solid-state NMR or NQR spectra of the polymorphs provides easy 
identification of polymorphic forms based only on the spectra recorded. More sophisticated 
analysis of the experimental solid-state NMR or NQR data often combined with modelling 
on the basis of quantum chemistry calculations (DFT or ab initio) can lead to the origin of 
differences in the structure of particular polymorphs.  
For the first time the differences in the SS NMR spectra being a result of polymorphism have 
been reported by Byrn et al. for benoxaprofen (non-steroidal anti-inflammatory drug), 
nabilone (antiemetic, an adjunct analgesic for neuropathic pain) and pseudo-polymorphism 
of cefazolin (first-generation cephalosporin antibiotic broad-spectrum) [129]. The method of 
choice was then PXRD, but surprisingly the solid-state 13C CP/MAS NMR spectrum of each 
polymorph was found to be distinctly different. These studies performed on bulk API 
material initiated more systematic studies of polymorphism by SS NMR. The first NQR 
studies of API polymorphism have been reported much earlier than those by SS NMR 
[130,131]. The first studied API was chloral hydrate (trichloroacetaldehyde monohydrate, 
2,2,2-trichloro-1,1-ethanediol), one of the oldest synthetic agents, a sedative and hypnotic 
drug. Significant improvement in sensitivity and resolution meant that both methods have 
become important complementary tools in the studies of polymorphism. SS NMR has been 
recently accepted by US and Japan Pharmacopeia as a method for polymorphism 
determination, NQR studies having been too scarce and not so popular.   
3.2.1.1 Packing polymorphism 
The packing polymorphism occurs when rigid molecules of the same conformation are 
packed in different ways in a crystal.  
Glycine 
An interesting example and the most intensively studied organic polymorph, is glycine, the 
simplest amino acid, a precursor to proteins, an inhibitory neurotransmitter in the central 
nervous system, anti-cancer, chronic multiple sclerosis and schizophrenia drug, also widely 
applied as excipient to drugs. In the solid state, glycine crystallizes in three forms , ǃ and Ǆ, 
which can be distinguished by XRD [132-134] or neutron diffraction [135,136]. The  form is 
stable, the ǃ form is unstable and readily transforms to  [132], while the Ǆ form is stable at 
room temperature, but irreversibly converts to  upon heating above 438K. The internal 
arrangement of molecules in layers is the same for , ǃ, which crystallize in monoclinic, 
P21/n and P21, respectively,  while Ǆ crystallizes with a trigonal hemihedral symmetry, in 
hexagonal, P31. In general, in all three forms the glycine molecules are zwitterions, the 
hydrogen-bonded double layers of molecules are packed by van der Waals forces and the 
only difference in the two forms results from the nature of the hydrogen bonding. 
Polycrystalline samples can be distinguished using X-ray powder diffraction [138] or 
infrared (IR) spectroscopy [133, 139]. The well-marked differences in the N–H stretching 
frequency in IR spectra (3164 cm-1 for -glycine, 3191 cm-1 for ǃ-glycine, and at 3105 cm-1 for 
Ǆ-glycine) allow fast identification of the polymorphs in a polycrystalline sample [140]. 
The polymorphs of glycine can be also distinguished using solid 13C NMR or 15N NMR by a 
direct comparison of the isotropic chemical shifts and/or chemical shift tensor components 
[139, 141]. However, the differences in these values are relatively small, at most of an order 
of 1ppm, Table 1. The sources of differences in the components of the chemical shift tensor, 
especially yy at 13C and zz at 15N for polymorphs have been revealed by the quantum 
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chemistry methods, DFT [142]. These differences have been explained by changes in the 
hydrogen bonding arrangement of -glycine and ǃ-glycine. In addition, polymorphs can be 
readily identified by the spin-lattice relaxation times 1H T1 and 15N T1 , which are much 
shorter for -glycine and ǃ-glycine than for Ǆ form. 
 
SITE FORM I 

FORM II 
ǃ 
FORM III 
γ 
iso 
[ppm]
xx 
[ppm]
yy 
[ppm]
zz 
[ppm]
T1, T1 
[s] 
iso 
[ppm]
xx 
[ppm]
yy 
[ppm]
zz 
[ppm]
T1, T1 
[s] 
iso 
[ppm]
xx 
[ppm]
yy 
[ppm]
zz 
[ppm] 
T1, T1 
[s] 
13C 176.5 
177.0 
176.5 
 
243.5 
244 
 
178.9
180 
 
108.7
105 
12 , 0.18 
(C=O) 
11, 0.043 
(NCH2) 
175.5 
175.4 
 
 
243.5
 
176.5
 
106.0
8, 0.012 
(C=O) 
2.3, 0.30 
(NCH2) 
174.5 
174.9 
174.6 
243.2
243 
174.9 
173 
106.6 
108 
55, 0.27 
(C=O) 
22, 0.053 
(NCH2) 
15N 32.3 
32.5 
 
40.2 
 
33.1 
 
24.3 
0.240 
0.93 
- - - - - 32.9 
32.8 
 
40.5 
 
33.6 
 
26.7 
0.150 
0.018 
Table 1. The isotropic chemical shifts and CSA tensor components, spin-lattice relaxation 
times T1, T1 -  in glycine forms , ǃ and Ǆ [140, 141]. 
The use of 14N NQR for differentiation of polymorphs is even much easier than the use of 
NMR, as the frequencies (ν), quadrupole coupling constants e2Qq/h and asymmetry 
parameters () for ǃ and Ǆ-glycine, are significantly higher than for  - form, Table 2. The 
changes in quadrupole coupling constants and asymmetry parameters reflect the differences 
in the hydrogen bonding length pattern. 
 
FORM I 
 
FORM II 
ǃ 
FORM III 
Ǆ 
ν+ 
[MHz] 
ν- 
[MHz] 
ν0 
[MHz]
e2Qq/h
[MHz] 
 
[-] 
ν+ 
[MHz]
ν- 
[MHz] 
ν0 
[MHz] 
e2Qq/h 
[MHz] 
 
[-] 
ν+ 
[MHz] 
ν- 
[MHz]
ν0 
[MHz] 
e2Qq/h 
[MHz] 
 
[-] 
1.100 0.785 0.315 1.257 0.501 1.133 0.843 0.290 1.317 0.440 1.044 0.822 0.222 1.244 0.357 
0.988 0.705 0.283 1.129 0.501   - - -   - - - 
Table 2. 14N NQR frequencies, quadrupole coupling constants and asymmetry parameters -  
in glycine forms , ǃ and Ǆ [143,144]. 
Acetazolamide 
An example of packing polymorphism is acetazolamide, the first non-mercurial diuretic 
drug, used clinically as antiglaucoma, antiepileptic or antiulcer, benign intracranial 
hypertension, altitude sickness, cystinuria and dural ectasia drug. Acetazolamide 
crystallizes in two polymorphic forms I and II [145], which differ in the spatial molecular 
arrangement and hydrogen bonding pattern, but not in the conformation of molecules. Thus 
the polymorphism of acetazolamide is classified as a packing type or pure combining 
association type. Interesting results concerning the interaction pattern have been obtained 
using NMR, NQR and DFT/QTAIM calculations [104]. The marked differences in the 14N 
NQR frequencies, quadrupole coupling constants and asymmetry parameters at the 
nitrogen sites in the thiadiazole ring and -NH2 on going from phase I to phase II allow 
distinction of both polymorphs, Table 3. Surprisingly the changes in the NQR parameters 
are negligible at -NH site. Moreover, the change in the parameters at the –NH2 nitrogen site 
is significant.  
As the source of this diversity can be either different hybridisation or participation in 
different hydrogen bonds or other weak intermolecular interactions, a detailed examination 
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of the closest-neighbourhood of each site in acetazolamide molecule was necessary. The 
XRD data were available but they could not explain the differences. Therefore each form 
was analysed within DFT/QTAIM, which shed some light on the bonding pattern in both 
polymorphs, Fig. 2. Table 3 [104].  
 
Form 
Nitrogen 
position
NQR 
T 
[K]
DFT 
B3LYP/6-311++G(d,p)* 
ν+ 
[MHz] 
ν - 
[MHz]
ν 0 
[MHz]
e2qQ/h
[MHz]
 
[-] 
e2Qq/h
[MHz]
 
[-] 
I 
-NH2 3.320 2.280 1.040 3.730 0.557 
295 
4.378 0.578 
-NH- 2.830 1.930 0.900 3.170 0.567 3.400 0.833 
N(4) 3.650 3.040 0.610 4.460 0.274 5.231 0.154 
N(3) 3.520 2.400 1.120 3.950 0.568 4.247 0.719 
II 
-NH2 3.555 2.515 1.040 4.045 0.514 
210 
4.321 0.678 
-NH- 2.840 1.940 0.900 3.190 0.565 3.375 0.827 
N(4) 3.660 3.070 0.590 4.490 0.263 5.218 0.166 
N(3) 3.570 2.510 1.060 4.050 0.523 4.263 0.706 
* cluster of 14 (form I) and 6 (form II) molecules 
Table 3. 14N NQR frequencies, quadrupole coupling constants and asymmetry parameters -
in acetazolamide form I at T = 295 K and acetazolamide form II at 210 K. 
   
FORM I     FORM II 
Fig. 2. Polymorphic structures of acetazolamide. 
In form I an –NH2 group (proton donor) forms a relatively strong NH…N hydrogen bond of 
3.080 Å in length with the nitrogen N(4) from the thiadiazole ring (hydrogen bond acceptor), 
i.e. that which does not participate in the formation of the molecular pair mentioned earlier. 
The additional two hydrogen bonds, NH…O, of 2.958 Å and 3.026 Å in lengths, are formed 
by the oxygen from a sulfone group as a hydrogen bond acceptor and N from -NH2 group 
as a hydrogen bond donor. In form II, the second of the two atoms in the 1,3,4-thiadiazole 
ring, N(4) (hydrogen bond acceptor) forms a very weak CH…N hydrogen bond of the 
length 3.695 Å at 93.2K with the carbon atom from -CH3 (hydrogen bond donor). Besides, 
two sulfonamide groups are bound by two identical N-H…O hydrogen bonds of the lengths 
2.988 Å and energy -20.8 kJ/mol at 93.2 K. Each -NH2 group forms also a bit stronger 
hydrogen bond NHO with a neighbouring acetyl group, of the length 2.896 Å and with the 
energy -28.4 kJ/mol at 93.2 K, Table 4..  
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FORM BOND  
[a.u.] 
() 
[a.u.] 
 
[-] 
E 
[kJ/mol] 
I 
RT 
Proton opt. 
N(4)…HC - - - - 
N(3)H….N(acetyl) 0.0319 0.084745 0.0727 -29.49 
S1…O( acetyl) 0.0258 0.082293 0.0035 -24.20 
II 
93.2 K 
Proton opt. 
N(4)…HC 0.0069 0.0211 0.0934 -4.72 
N(3)H….N(acetyl) 0.0408 0.1014 0.0682 -44.06 
S1…O( acetyl) 0.0200 0.0630 0.0510 -18.51 
I 
RT 
X-Ray 
N(4)…HC 0.0034 0.0115 2.3682 -2.55 
N(3)H….N(acetyl) 0.0182 0.0723 0.1108 -15.01 
S1…O( acetyl) 0.0259 0.0823 0.0038 -24.22 
II 
93.2K 
X-Ray 
N(4)…HC 0.0042 0.0134 0.1359 -2.96 
N(3)H….N(acetyl) 0.0325 0.1021 0.0827 -33.12 
S1…O( acetyl ) 0.0202 0.0622 0.0612 -18.22 
Table 4. Topological parameters of (r) for acetazolamide (the electron density at BCP (BCP 
(r), its Laplacian BCP(), the ellipticity of the bond () and estimated hydrogen bonding 
energy according to Espinosa (EE) calculated at the B3LYP/6-311++G(d,p) level of theory). 
Thus the largest differences in the symmetry of electron distribution between I and II forms 
should be observed at the -NH2 site. Indeed, the asymmetry parameter for -NH2 site is 
higher in I than in form II because in form I the nitrogen atom from -NH2 participates in 
three different intermolecular interactions, while in form II it participates only in two 
interactions. For the same reason e2Qqh-1 is smaller at -NH2 site in polymorph I in 
comparison to that in form II. Differences in bonding schemes of the terminal -NH2 group in 
the two crystallographic modifications are found to be responsible for a significantly 
different 14N NQR parameters, which can be used as a measure of the strength of hydrogen 
bonds [104].  
Cloxiquine 
An unusual case of packing polymorphism has been noted for cloxiquine (5-Chloro-8-
hydroxyquinoline) API of antibacterial, antifungal, antiaging and antituberculosis drugs. In 
the solid state, cloxiquine crystallizes in two forms I and II differing in the arrangement of 
rigid molecules. Both forms can be easily distinguished by XRD [145]. In both forms the 
hydroxyl hydrogens are capable of forming a multicentre i.e. bifurcated O-H...N hydrogen 
bonds, one intramolecular and the other intermolecular, which simultaneously lead to 
formation of five-membered hydrogen-bonded chelate rings [N, C(9), C(8), O, H(8)] and to 
dimerisation of the molecules. Such patterns, usually termed supramolecular synthons [146], 
are according to XRD data,  independent of the polymorphic form, however in the dimeric 
structure of cloxiquine form I the paired molecules in the units are twisted, while in form II 
they are not. Due to this subtle difference in the planarity of dimeric structures which 
consist of the paired molecules linked by bifurcated hydrogen bonds in the units - twisted in 
form I, and planar in form II [146], accompanied by change in the hydrogen bond lengths, 
the structure units can be differently packed to yield the two polymorphs. XRD indicated 
that the supramolecular synthons expand into a column by - stacking interactions, along 
the crystallographic c axis in I and b axis in II [146]. The columns constructed in this way are 
stabilized in the 3D crystal structure by Van der Waals forces.  
The pronounced differences in 14N and 14O NQR spectra (frequency shifts: 0.175, 0.156, 0.020 
and 0.107, 0.234, 0127 MHz, respectively) but only slight in 35Cl (frequency shifts by 
0.033MHz) allows distinction between forms I and II [148]. The elongation of the hydrogen 
bond in form I in comparison to form II is reflected by a change in the asymmetry 
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parameter. DFT/QTAIM formalism was applied to study supramolecular synthon pattern 
in detail and estimate the strength and character of hydrogen bonds. The intramolecular N-
H…O bonds in cloxiquine form II are weak and slightly stronger than the intermolecular N-
H…O bonds, but generally weaker than typical and mainly electrostatic ones, while 
intermolecular N-H…O bonds in cloxiquine form I are moderate and partially covalent in 
nature. The large differences in strength of the corresponding H-bonds in both cloxiquine 
forms, suggest the interplay in H-bonds linking adjacent molecules in dimers, Fig. 3. The 
strong interactions between monomers being components of supramolecular synthon of 
cloxiquine form II, i.e. the two competitive (intra- and intermolecular) O-H...N hydrogen 
bonds, the former slightly stronger than the latter, and an additional intermolecular 
hydrogen bond C-H..O, which in contrast to form I links atoms in the same dimer and thus 
is more than twice stronger, are responsible for drastic differences in polarity of 
supramolecular synthons and result in the planarity of form II. Moreover, the strength of 
stacking Ǒ···Ǒ interactions is found to be strongly dependent on planarity thus they are 
much weaker in form I than in form II of cloxiquine. The NQR parameters have been 
correlated with both the molecular density of the packing and the distance between stacking 
layers, as a consequence of different hydrogen bonding strength and different Ǒ···Ǒ overlaps 
[148]. Both forms differ in water solubility and dissolution rate (form II is 1.47 times better 
soluble than form I) [146]. 
 
  
          FORM I    FORM II 
Fig. 3. Polymorphic structures of cloxiquine. 
3.2.1.2 Conformational polymorphism 
Conformational polymorphism occurs when flexible molecules with different conformations 
are packed in different ways in the same crystal unit.  
The group of sulfonamides, of well-known antibacterial activity, make a good illustration of  
conformational polymorphism. These compounds have been more or less systematically 
studied since their discovery in the late 1930s. Till 1948 more than 5,000 derivatives have 
been synthesised, among which several drug classes have been identified (e.g. antibacetrial, 
hypoglycemics, carbonic anhydrase inhibitors, saluretics, and tubular transport inhibitors). 
The antibacterial effectiveness of sulfonamides, classified as the sulfa drugs, is determined 
by a highly polar sulfonyl group, which is responsible for the similarity of sulfonamides to 
the p-aminobenzoate ion. Their intermolecular interactions patterns have some common 
features i.e. amido protons show a greater preference for hydrogen bonding to amidine 
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nitrogens and cocrystal guests, whereas the amino protons show a greater preference for 
hydrogen bonding to sulfonyl oxygens [149]. The dominant hydrogen-bond pattern is a 
chain with an eight atom repeat unit. Molecules of sulfonamides are extraordinarily 
versatile due to conformational (amine and amide) and hydrogen-bonding capabilities. 
Thus sulfonamides reveal the ability to crystallize in multiple solid-state structures i.e. 
exhibit polymorphism. In fact many polymorphs and hundreds of solvates have been 
discovered for this class of compounds [102].  
Sulfanilamide 
The most intensively studied compound from this class is sulphanilamide (4-
aminobenzenesulfonamide) - a sulfonamide antibiotic used in treatment of streptococcal 
infections. In the solid state, it crystallizes in four forms ǂ, ǃ, Ǆ, [149-151] and ǅ [152-154] 
fully investigated by XRD. The different d-spacing of three strongest XRD diffraction lines 
(4.91, 6.57, 3.57; 6.12, 4.49, 4.23; and 3.90, 3.78, 33.6 for ǂ, ǃ, Ǆ, respectively) allows easy 
distinction of each polymorph. The form stable at room temperature is ǃ- sulfanilamide. The 
remaining forms gradually revert to this form on storage. On slow heating, ǃ-sulfanilamide 
slowly transforms to ǂ and then to Ǆ. The forms ǃ and Ǆ are considered to be 
enantiotropically related. The origins of polymorphism of sulfanilamide were found to be 
connected with the versatile hydrogen-bonding capabilities [154]. The differences in the 
chemical shifts at 13C and at 15N permitting the distinction between individual polymorphs 
Table 5, [156] are of the same order as in glycine. However, the chemical shifts at N(1) site 
were almost the same for the three polymorphs. The spin-lattice relaxation times 1H T1 and 
1H T1 allow distinction of ǃ-sulfanilamide from the other polymorphs, while 15N T1 allows 
distinction of all three polymorphs and what is more, point to substantial differences in 
mobility around N(1) and N(2) sites. This result has pointed to different molecular mobility 
in the solid-state at  each site in each polymorph. 
 
ISOT. SITE FORM I 
 
FORM II 
ǃ 
FORM III 
γ 
iso 
[ppm] 
 
[ppm]

[-]
T1, T1 iso 
[ppm] 
 
[ppm]

[-]
T1, T1
 
iso 
[ppm] 
 
[ppm] 
 
[-] 
T1, T1 
 
13C C(1) 
C(4) 
C(2),C(6) 
C(3),C(5) 
153.7 
128 
113.1, 115.3
128.3 
- - - 153.4 
127.1 
112.3,117.1 
129.5 
- - - 151.0 
127.1 
112.7, 115.1
129.6 
- - - 
C(1) 
C(4) 
C(2),C(6) 
C(3),C(5) 
166.5,157.6 
134.5 
118.8, 124.0
134.5 
- - - 165.5, 156.0
135.6 
118.3,123.1 
133.3 
- - - 165.5, 156.0
137.1 
120.0, 122.5
135.0 
- - - 
15N N(1) 
N(2) 
-312.2 
-288.8 
46 
70 
1
0.4
0.64ms
6.5ms 
-312.1 
-284.1 
43 
71.2 
0.8
0.4
0.64 ms
10ms 
-312.1 
-280.6 
45 
67.3 
1 
0.3 
1.5 ms 
4.2ms 
1H -- - -  94 s 
7.2 s 
- - - 8 s 
7.1 s 
- - - 82 s 
3.0 s 
Table 5. The isotropic chemical shifts and CSA tensor components - in sulfanilamide forms 
, ǃ and Ǆ [156].  
The pronounced differences in 14N NQR spectra, Table 6, [157] make the differentiation of  
and ǃ polymorphs of sulfanilamide much easier than with the use of SS NMR. The shifts in 
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frequencies (ν) and differences in quadrupole coupling constant e2Qq/h and asymmetry 
parameter () with reference to those of  form (0.555, 0.522, 0.410 and 0.693 MHz) are evident.  
 
FORM I 
 
FORM II 
ǃ T 
[K] ν 
[MHz] 
e2Qq/h
[MHz]
 
[-] 
ν 
[MHz]
e2Qq/h
[MHz]
 
[-] 
3.460 
2.527 
0.933 
3.990 
 
 
0.47
 
 
2.905 
2.005 
0.900 
3.270 
 
0.55
 210 
3.115 
2.603 
0.512 
3.810 0.27 2.705 
1.910 
0.790 
3.080 0.51
255 
Table 6. 14N NQR frequencies, quadrupole coupling constants and asymmetry parameters - 
in sulfanilamide form I at T = 295 K and form II at 210 K [156]. 
Thus NQR seems an even more suitable technique for identification of polymorphs and 
studies of changes in the intermolecular pattern due to polymorphic transitions.  
While the number of drugs studied by solid state NMR is large, 14N NQR was successfully 
applied for the studies of a group of sulfonamides exhibiting confomational polymorphism 
including sulfapyridine (4-amino-N-pyridinylbenzene sulfonamide), sulfadiazine (4-amino-
N-pyrimidin-2-yl-benzenesulfonamide), sulfamerazine (4-amino-N-(4-methylpyrimidin-2-
yl)benzenesulfonamide), sulfamethazine (4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-
sulfonamide), sulfathiazole (4-amino-N-(1,3-thiazol-2-yl)benzenesulfonamide)[157]. 
Interesting results have been also obtained for non-steroidal anti-inflammatory drug 
piroxicam ((8E)-8-[hydroxy-(pyridin-2-ylamino)methylidene]-9-methyl-10,10-dioxo-10λ6-
thia-9-azabicyclo[4.4.0]deca-1,3,5-trien-7-one) [158]. 35Cl NQR was successfully applied in 
the study of chloral hydrate (trichloroacetaldehyde monohydrate, 2,2,2-trichloro-1,1-
ethanediol), one of the oldest synthetic agents of sedative and hypnotic effects [130], non-
steroidal anti-inflammatory diclofenac (2-[2-(2,6-dichlorophenyl) aminophenyl] acetic acid) 
[159], anti-diabetic chloropropamide (1-(4-chlorophenyl)sulfonyl-3-propyl-urea) [159], 
diuretic furosemide (4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid) [160]. 
Differentiation of the polymorphic forms of these compounds is not difficult because of a 
distinct shift in the 14N-NQR or 35Cl NQR frequency (0.65, 0.425, 0.58 and 0.18MHz for 
sulfamerazine, 0.23, 0.48, 0.42, 0.30, 0.10 and 0.08MHz for sulfathiazole, and 0.142MHz for 
furosemide; 0.287MHz for chloral hydrate, 0.176MHz for diclofenac, 0.306 MHz for 
chloropropamide) while, at the accuracy of determination of the order of  0.001 MHz (14N 
NQR) and 0.010 MHz (35Cl NQR) even for broad lines.  
Apart from typical NQR parameters, polymorphs are often readily identified (similarly as in 
NMR study) on the basis of changes in the NQR linewidth (1.5kHz for sulfapyridine, 10kHz 
for chloropropamide) or in the spin-lattice (sulfapyridine 70-fold, chloropropamide 2-fold) 
or spin-spin (chloropropamide 10%) relaxation times. However, sometimes the estimation of 
the amount of polymorphs in a mixture on the basis of these parameters can be misleading 
[156].  
It is known that in some cases SS NMR was helpful in explaining contradictions concerning 
polymorphism following from IR, XRD and DSC studies [118]. A briliant example indicating 
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the usefulness of SS NMR is cefinidir, a broad-spectrum antibiotic, proven effective for 
common bacterial infections of the ear, sinus, throat, and skin. The use of XRPD and IR was 
not sufficient and Abbott’s 'new polymorph' discovered using these techniques in 2003 was 
proved to be not a polymorph, but a pyridinium salt. [118]. Up to now no examples of such 
spectacular NQR applications had been given, but it does not mean that the potential of this 
method will not be exploited for this purpose in future.  
Solid-state NMR or NQR can be powerful methods for comparing physical forms of the 
drug substance after pharmaceutical processing or manufacturing. Variation in the chemical 
shift or NQR frequency from polymorph to polymorph allows identification of differences 
in the atomic environment. In addition, NMR and NQR are quantitative analytical 
techniques, i.e. the intensity of their respective signals is directly proportional to the number 
of nuclei in the sample [158,160,161]. Thus it is possible to estimate the quantitative 
polymorphous composition or a relative proportion of polymorphs in a sample and the 
result is reliable. NMR is an important spectroscopic tool for the study of solid-state drug 
formulations. NQR method has such a potential. Both methods can be used for analysis of 
pure API or mixtures of polymorphs in pure drug substance and in dosage formulations. A 
detailed analysis of this aspect of NMR or NQR applications is beyond the scope of this 
chapter. 
3.2.2 Tautomerism 
Tautomerism (Greek: tautos-identical; isomerism - Laar, 1985 [162]) can be defined as a 
reversible structural isomerism involving the sequential processes of bond cleavage, skeletal 
bond migration and bond reformation. Tautomerisation plays an important role in 
mutations or enzymatic reactions. Thus the inspection of the most stable tautomeric forms 
allows further discussion of the functional implications of tautomerism for recognition and 
binding to DNA, proteins or enzymes. Many purines and pyrimidines occur in tautomeric 
forms whose relative stabilities depend on the environment. Any alteration or modification 
in the base pairing scheme of DNA due to the existence of different tautomeric forms also 
may result in perturbation to the replication process or spontaneous mutations, i.e. to a 
reduced stability of DNA. The presence of an abnormal tautomer can be even more 
deleterious to the stability of DNA. On the other hand, these unique capabilities of 
modifying DNA may be relevant for the process of designing of DNA binding drugs of 
distinct antitumor efficacy. The fact that often the less abundant tautomer is the most 
reactive one (Hammond rule [126]) further reinforces the relevance of investigation of 
intermolecular interactions in the solid state. The preference for different tautomeric forms 
is a clear indication of the importance of intermolecular interactions, in particular H-
bonding, in determination of the structure of the condensed phase.  
Polyhalobenzimidazoles 
An example are the studies of annular tautomerism of polyhalobenzimidazoles, Fig.4, [105]. 
NQDR and DFT results have suggested the presence of prototropic annular tautomerism 
50:50, which is in a good agreement with the XRD and 1H-NMR data. According to the XRD 
data, all halogenobenzimidazole crystals are isostructural and have the same space group 
I41/a. The intermolecular hydrogen bonds N1-H···N3’ and N1’···H-N3 which link each 
molecule with two neighbouring ones, occur between the molecules related by the fourfold 
screw symmetry axis along the c direction of the tetragonal cell, Fig. 4. According to QTAIM 
analysis, the N-H···N bonds formed by both nitrogen atoms (N1 and N3) differ 
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insignificantly in strength (by less than 0.4 kJ/mol), which is in a good agreement with the 
differences in their lengths.  
Comparison of the HB strength and electron density at the hydrogen bond critical points in 
a group of polyhalogenobenzimidazoles suggests that hydrogen bonds are of similar 
strength. The differences in e2Qqh-1 and η observed for both nitrogen sites suggests that 
hydrogen bonds are asymmetric and should be described by a proton double minimum 
potential, which is confirmed by the QTAIM analysis. As the compounds crystallise in the 
centrosymmetric group, the polar chains of the molecules arranged in one direction are 
accompanied by antiparallel chains arranged in the opposite direction and this spatial 
ordering is very close to that observed in the ǂ form of 1H-benzimidazole. This suggests that 
a packing polymorphism similar to that in 1H-benzimidazole can be expected in 
polyhalogenobenzimidazoles. Additionally QTAIM calculations have revealed weak 
intermolecular interactions in polyhalogenobenzimidazole structures i.e. N···X (X = H, Cl, 
Br or I) and two kinds of Y···Z (Y, Z=Cl, Br or I) contacts, which are much weaker than 
hydrogen bonds. The local potential energy density at BCPs indicated the following 
ordering of the intermolecular interactions according to increasing bond strength (E) : 
N1-H···N3 ~ N1-H···N3 < N1···X < X···Y (X, Y from the same ring) < X···Y (X, Y from the 
different rings). The pattern of intermolecular contacts has been found responsible for the 
specific crystal arrangement and the annular prototropism [105].  
 
 
Fig. 4. The intermolecular hydrogen bonds pattern in polyhalogenobenzimidazoles. 
2-thiocytosine and cytosine  
The solid-state tautomerism studies are well illustrated by those performed for canonical 
natural nucleic acid base cytosine, and its analogue 2-thiocytosine. The replacement of 
cytosine by 2-thiocytosine may perturb base-pairing process of DNA or it can produce 
spontaneous mutations i.e. reduced stability of DNA. The compound of 2-thiocytosine is a 
potential anti-leukaemic and anticancer agent [163,164]. Numerous derivatives including 1-
(-D-arabinofuranosyl)-2-thiocytosine and its analogues and complexes with trimethyl 
platinum have been synthesized and their enzymatic reactivity and antitumor activity have 
been studied [165]. The cytotoxic activity of some of them has been found even higher than 
that of cisplatin and was manifested even against cisplatin resistant cell lines [165].  The 
arrangement of molecules in the crystals of 2-TC is essentially the same as that found for 
cytosine, but more complicated due to the existence of two inequivalent molecules in the 
elementary cell, Fig. 5, [166].  
www.intechopen.com
 
Towards Understanding Drugs on the Molecular Level to Design Drugs of Desired Profiles 
 
257 
In the 2-thiocytosine crystalline structure, supramolecular synthons (dimers) are linked to 
the neighbouring supramolecular synthons by intermolecular interactions of the same 
pattern i.e. weaker H-bonds: N(1)-H(1)...N(3') and N(4')-H(4')...S(2) of 3.114 and 3.408 Å. 
Neighbouring ribbons are linked together by much longer, thus considered weak, N-H...S 
bonds of the lengths 3.466 and 3.551 Å [166]. The application of QTAIM allows detection 
and distinction of many weaker interactions in the crystalline structure of 2-thiocytosine 
[167], which was not possible in a standard X-Ray study [166]. Indeed in the crystalline 
structure of 2-thiocytosine, the QTAIM analysis has revealed the presence of four varieties 
of intermolecular interactions not involving hydrogen atoms (N…N, N…C and N…S), apart 
from the hydrogen-bonds (N-H…N, N-H…S, C-H…S and C-H…C).  
 
    
2-THIOCYTOSINE                                               CYTOSINE 
Fig. 5. Arrangement of molecules in the crystals of 2-thiocytosine and cytosine. 
In general, the hierarchy of structures in crystals of 2-thiocytosine molecules-dimers-
ribbons-stacks is reflected by the progressively weaker bonds. The N(1')-H(1')…N(3) 
interaction is found to be the strongest (-23.18 kJ/mol), followed by N(4)-H(4)...S(2') (-17.13 
kJ/mol). The third H-bond linking adjacent molecules into a dimer C(6)-H(6)…S(2'') of 3.532 
Å (-9.43 kJ/mol) is much weaker and thus not revealed by X-ray [165]. The hydrogen bonds 
linking adjacent supramolecular synthons are: N(1)-H(1)...N(3') of 3.114 Å and -16.10 
kJ/mol, N(4')-H(4')...S(2) of 3.408 Å and -13.95kJ/mol. The H-bonds linking neighbouring 
ribbons are: N(4)-H(4)...S(2’) of 3.466 Å (-3.17 kJ/mol) and 3.551 Å (-8.01 kJ/mol) and C(5)-
H(5)...S(2’) bond of length 4.037 Å (-2.85 kJ/mol), two C(5)-H(5)...C(6’) and C(5’)-H(5’)...C(6) 
of 3.688 Å (–3.99 kJ/mol) and 3.943 Å (-1.91 kJ/mol), respectively. Additionally between 
layered dimers a few - interactions involving non-H atoms, purely van der Waals in 
nature, were detected: N(1)…N(3”), N(1)…C(5”) and N(3)…S(2”) of the lengths 4.094, 3.411 
and 3.516 Å and roughly estimated energies -1.14, -4.06 and -4.01 kJ/mol [167]. It is worth 
noting that N(4) from the NH2 group, in contrast to N(1) and N(3), does not participate in 
this stacking - interactions. The differences between the isosurface representations of 
Laplacian at nitrogen sites in both inequivalent molecules are small, however they suggest 
that –NH- site exhibits more symmetrical electron density distribution in molecule A than B, 
while –N= and -NH2 sites exhibit more symmetrical distribution in molecule B than A, 
which is in a good agreement with experimentally obtained results [167].  
www.intechopen.com
 
Drug Discovery and Development – Present and Future 
 
258 
3.2.3 Stability 
The term 'stability' of drugs refers to their chemical and physical integrity and can be 
influenced by many factors (temperature, light, air, humidity and pressure), as well as the 
package components. In the pharmaceutical context the influence of temperature and /or 
irradiation is of particular interest. These factors can lead to the transition to undesirable 
meta-stable polymorph or degradation products, which means reduction of bioavailability, 
loss of activity or even toxicity.  
3.2.3.1 Thermal stability 
Solid state NMR and NQR are particularly well suited for fast monitoring of temperature 
effect on the thermal stability of API. Temperature studies of chemical shifts on different 
isotopes, or 1H NMR second moment or 35Cl or 14N NQR frequencies or different spin-lattice 
relaxation times  (r.g. T1(1H NMR), T1(35Cl NQR) or T1(14N NQR)) provide the information 
on the compounds stability, including the phase transitions (changes in the crystallographic 
structure and ordering). For many vitamins and drugs, the temperature dependencies of 
second moment of 1H NMR or spin-lattice relaxation time have been studied along with 
molecular motions - hindered rotations, reorientations, proton transfer, but the 
pharmaceutical context has been neglected. Similarly, for a few APIs including urotropine 
(HMT), an antiseptic used for the prophylaxis of urinary tract infections, or chloral hydrate - 
a local anaesthetic, the temperature dependencies of NQR frequency and phase transition 
have been studied more or less systematically [168-170], but not in the pharmaceutical 
context.  
The thermal stability aspect most important and interesting from the pharmaceutical point 
of view is the phase transitions of APIs, especially the uncontrolled ones. The unstable 
polymorphs often convert into more stable ones by phase transitions.  Uncontrolled 
polymorph transitions of API may happen during the final crystallisation, storage in the 
parent solution, drying, wet granulation, micronization, tablet pressing, or even in shelf life 
(storing). In general two types of polymorphous transitions are distinguished the 
enantiotropic and the monotropic ones. The enantiotropic transition occurs at a specific 
temperature at which the originally more stable polymorph transforms into another finally 
stable polymorph. Transitions of this type are often reversible and well-defined. The second 
type of polymorphous transitions, the monotropic one does not occur at a specific 
temperature in solid state. The polymorph transition passes over the liquid phase, which 
means crystallisation from a different solvent. Most of polymorphous transitions of APIs are 
monotropic and not enantiotropic which is a negative phenomenon. 
Interesting results have been obtained for hydrochlorothiazide (HCTZ), a diuretic drug 
applied to beat high blood pressure and heart failure. Among the DTA, NMR, NQR and 
XRD methods [171,172] the most sensitive to its phase transitions was NQR [172]. The 
anomalies in the temperature dependence of the 35Cl NQR frequency for HCTZ, the change 
in the linewidth (being a result of an increase in the spin-lattice relaxation time), small but 
notable changes in the slope and the jump in frequency observed at 253 K, not exceeding 
0.05 MHz, together with the lack of hysteresis (which distinguishes the first- and second-
order transitions) indicated a second-order transition. This transition was not revealed by 
the temperature dependencies of the 1H second moment or 1H spin-lattice relaxation time 
(NMR), which were able to detect only trans-gauche jumps of -NH2. Moreover, the phase 
transition clearly visible in NQR was only weakly indicated by the thermal dependence of 
heat capacity (DTA measurements) [171]. This phase transition was interpreted as a change 
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in the structural ordering connected with the reorientation of the -NH2 group in a specific 
temperature in solid state i.e. the enantiotropic one. Indeed, in a short time after detection of 
the conformation phase transition, the polymorphs of HCTZ, Fig. 6, have been crystallised 
and their structure by XRD have been resolved [173]. Thus the NQR studies contributed to 
the evidencing of polymorph transforms and understanding of the nature of phase 
transition. 
                 
FORM I              FORM II 
Fig. 6. Polymorphic structures of hydrochlorothiazide. 
Another interesting case is chloropropamide for which NQR was able to detect not only the 
A to C phase transition, but also different molecular dynamics manifested as a difference in 
the slope of the temperature dependencies of NQR frequencies for A and C polymorphs 
[159]. Temperature dependencies of NQR frequencies can also bring information on the 
stability of a compound studied. For instance, a smooth temperature dependence of NQR 
frequency for triclosan suggests that its ring maintains almost the same conformation in the 
temperature range studied (no ring rotation), which has been confirmed by XRD results [98].  
One more interesting example illustrating the potential of molecular dynamic NQR studies 
are the results obtained for antipsychotic and antihistaminic drug – phenothiazine [174]. 14N 
NQR frequencies measured in both the low- and high-temperature phases indicated the 
presence of large thermal librations of the phenothiazine molecules in both crystallographic 
phases as well as an order-disorder phase transition associated with reorientations of the 
quite rigid phenothiazine molecules [175] around the orthorhombic axis. The quadrupole 
coupling constant have not been affected by the phase transition, while the asymmetry 
parameter reflected this phase transition even more evidently than the 14N NQR frequencies. 
Thus the NQR studies contributed to the understanding of the microscopic mechanism of 
the phase transition.  
3.2.3.2 Photostability 
In the solid state, the temperatures required for different types of degradation differ, thus 
the mechanisms of thermal and photochemical degradation are expected to be different. 
Because light irradiation of drugs is known to have a very strong, often negative effect on 
their activity, the integral part of research on API are photostability studies. Photostability of 
API depends on the factors connected with the irradiation features (wavelength, intensity 
and time of exposure) as well as on a variety of physico-chemical features characterising the 
API substance itself (formulation type: solution, powder, crystal; presence of specific 
molecular fragments). Although a large number of drugs have the form of solid 
formulations, most studies on photostability have been performed in  artificial conditions, 
i.e. in dilute solutions in specific organic solvents in which such processes can be easily 
www.intechopen.com
 
Drug Discovery and Development – Present and Future 
 
260 
observed. However, it should be mentioned that in such conditions the drug’s photostability 
may be totally different than in solid. Even the addition of excipients may affect the 
photostability of drug formulation. 
The main phenomenon responsible for deterioration of the useful properties of a drug, that 
is the loss of its activity or increased toxicity, is photodegradation. Photodegradation of a 
drug is significant under irradiation with light of wavelength longer than 330 nm. However, 
even in such favourable conditions, photoreaction can be easily unnoticed when it is very 
slow, especially in solid state. The typical approach to study photodegradation is based on a 
combination of different techniques. The widely applied procedure includes studies of 
photodegradation products using different techniques including chromatographic 
techniques  gas/liquid chromatography (GLC), thin layer/chromatography (TLC) or high 
pressure liquid chromatography (HPLC), electron paramagnetic resonance (EPR), 
differential thermal analysis (DTA), nuclear magnetic resonance (NMR), and Fourier 
transform infrared reflection absorption spectroscopy (FT-IR RAS). Although the above 
mentioned methods are very sensitive but they require the use of solvents which may cause 
further degradation of drug during the analysis. The alternative for the identification of 
photodegradation products are solid state methods, which allow credible identification of 
the compounds in solid, guaranteeing elimination of the above mentioned solvent side 
effects.  
An interesting example illustrating the studies of photostability is nifedipine, mainly used 
for treatment of hypertension, coronary heart/artery diseases and arrhythmias, or as 
cardiovascular organ-protective agent [176]. Nifedipine is known as one of the most 
photolabile APIs, extremely sensitive to UV-VIS radiation up to 450 nm and to the ionising 
radiation. The loss of therapeutic properties by NIF due to photodegradation is well 
documented [177]. The photodegradation of NIF in solution has been widely studied [178] 
whereas only a few authors have studied it in solid [179]. The photostability and the 
photostabilization of NIF in different solid formulations including powders and tablets have 
received considerable attention [180]. A typical approach to study these phenomena is based 
on a combination of different techniques. The products of photodegradation are studied 
using different techniques including EPR, DTA, NMR, FT-IR-RAS but the isolation of the 
products is performed by chromatographic techniques: gas/liquid chromatography (GLC), 
thin layer/chromatography (TLC) or high pressure liquid chromatography (HPLC).  
Unfortunately, solid 13C NMR is not always able to detect the photoproducts. A striking 
example is nifedipine whose degradation effect manifested as shifts of signals assigned to 
C(4), C(3) and C(5) as well as C(2') sites was observed only in solution [181]. Instead, a 
combination of 14N NQDR and DFT methods proved to be effective because the nitrogen 
sites in nifedipine and its photoproduct differ significantly, (-NH- versus -N= and -NO2 
versus -NO). 14N NQDR seems the best experimental method of choice for non-destructive 
detection of NIF to NO-NIF photoconversion in solid [182]. It is worth noting that the 
electron density distribution at the -N=, -NH, -NO2, -NO sites can be accurately and fully 
experimentally evaluated using this technique. Thus 14N NQDR should be of particular 
importance for the studies of photodegradation of solid drugs, especially nitro-compounds. 
Additionally within QTAIM formalism it has been possible to predict the sites in nifedipine 
most affected by irradiation -NH, -NO2 and -CH. 
It is known that NQR is suitable for determination of the degree of 35Cl release from a given 
pharmaceutical under the effect of UV irradiation, which is manifested as a decrease in the 
signal intensity or even as its disappearance (e.g. for furosemide), but when the radicals 
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formed undergo fast recombination the relevant changes in the NQR spectra are 
undetectable (e.g. thiazides). 
4. Conclusions 
According to James Black, a Nobel laureate in Physiology or Medicine 1988, ‘The most fruitful 
basis for the discovery of a new drug is to start with an old drug.’ [183]. Actually among 700,000 
crystal structures from monatomic metals to proteins and viruses systematically collected 
from the late 1960s and early 1970s are available in five comprehensive and fully 
retrospective world depositories: Cambridge Structural Database (CSD), Worldwide Protein 
Data Bank (wPDB), Nucleic acid database (NDB), Metals and intermetalics database 
(CRYSTMET) and Inorganic Crystal Structure Database (ICSD) only about 10% are 
structures of APIs and targets. The largest database, CSD, nowadays contains over 500,000 
structures ("small molecules" - less than 1000 atoms) of which 99% were determined by XRD 
[61,62]. The number of drug-like structures in CSD exceeds 60,000. The largest protein 
archive, wPDB, contains 73,699 experimentally-determined structures of proteins, nucleic 
acids, and complex assemblies, of which 87% were determined by XRD, 12% by NMR, less 
than 1% by electron microscopy and hybrid methods.  
Thus among the large number of known, classified drugs and targets only a small fraction 
has been investigated using SS NMR and even a smaller one - using NQR. In fact the 
application of both methods in drug development studies has definitely a short history. 
Despite this, significant improvements in the past few years, resulting in a remarkable 
enhancement of the speed and the efficacy of this approach permit expecting a great  
increase in its role in the near future. SS NMR and NQR in combination with computational 
methods like ab initio or DFT will play a crucial role in modern crystallography and 
medicinal chemistry. An important advantage of SS NMR or NQR spectroscopy over XRD, 
is that SS NMR and NQR spectroscopies are sensitive to local or short-range order (<5 Å), 
while XRD detects comparatively long-range order (>100 Å). Thus SS NMR and especially 
NQR provides unique insight into intermolecular interactions that are not easily obtained by 
other methods. A combination of experimental and theoretical techniques has certainly 
much to offer for the studies of drugs or potential drugs in early phases of drug research. 
Their capabilities in particular when applied to the known drugs, have been well 
documented in literature [92,99,101,104,105,148,156-161,184-189]. 
Although in some fields the NMR or NQR are not competitive to IR, UV or XRD the 
examples of combined studies given above show that both techniques have a potential to 
elicit structural and physico-chemical information about a molecule of dug, target or the 
interaction drug-target.   
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